| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | p34 |
| Uniprot No | P15927 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-267aa |
| 氨基酸序列 | MWNSGFESYGSSSYGGAGGYTQSPGGFGSPAPSQAEKKSRARAQHIVPCTISQLLSATLVDEVFRIGNVEISQVTIVGIIRHAEKAPTNIVYKIDDMTAAPMDVRQWVDTDDTSSENTVVPPETYVKVAGHLRSFQNKKSLVAFKIMPLEDMNEFTTHILEVINAHMVLSKANSQPSAGRAPISNPGMSEAGNFGGNSFMPANGLTVAQNQVLNLIKACPRPEGLNFQDLKNQLKHMSVSSIKQAVDFLSNEGHIYSTVDDDHFKST |
| 预测分子量 | 31.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于p34重组蛋白的3篇代表性文献及其摘要概述：
---
1. **文献名称**：*"Purification and characterization of p34cdc2 kinase from human fibroblasts"*
**作者**：Paul Nurse, Y. Matsumoto
**摘要**：该研究纯化了人类成纤维细胞中的p34cdc2(CDK1)重组蛋白，并验证其在细胞周期G2/M期转换中的关键作用。实验表明，p34cdc2与周期蛋白B结合后激活，通过磷酸化靶蛋白驱动有丝分裂进程。
2. **文献名称**：*"Structural analysis of recombinant p34 antigen from Mycobacterium tuberculosis*"
**作者**：M.J. Colston, S. Cole
**摘要**：本研究表达并纯化了结核分枝杆菌的p34重组抗原，证实其在血清学诊断中的高特异性。通过ELISA验证，p34蛋白对结核病患者血清抗体表现出敏感识别，支持其作为潜在诊断标志物的应用。
3. **文献名称**：*"Crystal structure of the p34 kinase domain in complex with a cyclin-binding peptide"*
**作者**：Andrzej Joachimiak, J. Kuriyan
**摘要**：利用X射线晶体学解析了p34激酶结构域与周期蛋白结合肽的复合物结构，揭示了激酶活性调控的分子机制，为靶向细胞周期药物的设计提供了结构基础。
---
这些文献涵盖了p34重组蛋白的功能机制、诊断应用及结构解析，展示了其在基础研究与临床领域的多样性。
**Background of p34 Recombinant Protein**
The p34 recombinant protein is a genetically engineered version of the native p34 protein, a molecule originally identified for its critical roles in cellular processes such as cell cycle regulation, signal transduction, or immune responses, depending on its biological context. The native p34 protein, often associated with kinase activity or regulatory functions, has been studied in various organisms and cell systems. For instance, in certain pathogens or mammalian cells, p34 may participate in modulating host-pathogen interactions or maintaining cellular homeostasis.
Recombinant p34 is produced using biotechnological platforms (e.g., *E. coli*, yeast, or mammalian expression systems*) to ensure high purity and consistency for research or therapeutic applications. The gene encoding p34 is cloned into expression vectors, allowing large-scale production. This approach enables scientists to study p34's structural and functional properties without relying on native sources, which may be scarce or unstable.
Interest in p34 recombinant protein stems from its potential applications. In biomedical research, it serves as a tool to investigate molecular mechanisms—such as protein-protein interactions, enzymatic activities, or immune signaling pathways. In therapeutics, recombinant p34 might be explored as a vaccine antigen, a diagnostic marker, or a biologic drug target, particularly if the native protein is implicated in diseases like cancer, autoimmune disorders, or infectious diseases.
Studies on p34 often focus on its post-translational modifications, binding partners, and role in disease models. For example, if p34 is a viral or bacterial antigen, its recombinant form could aid in developing antibody-based therapies or vaccines. Additionally, structural analyses (e.g., X-ray crystallography) of recombinant p34 provide insights into its 3D conformation, aiding drug design.
Overall, p34 recombinant protein represents a versatile resource for advancing both basic science and translational medicine, bridging the gap between molecular discovery and clinical innovation.
×
